Literature DB >> 30061775

Broad Phenotypic Heterogeneity and Multisystem Involvement in Single mtDNA Deletion-associated Pearson Syndrome.

Josef Finsterer1, Fulvio A Scorza2, Carla A Scorza2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30061775      PMCID: PMC6021152          DOI: 10.5455/medarh.2018.72.234-236

Source DB:  PubMed          Journal:  Med Arch        ISSN: 0350-199X


× No keyword cloud information.
We read with interest the article by Khasawneh et al. about a 4 months-old male with Pearson syndrome due to a novel mtDNA deletion (1). We have the following comments and concerns. The authors mention that Pearson syndrome may be due to mtDNA point mutations (1). We do not agree with this notion. If at all, this is a completely rare event. In the vast majority of the cases, Pearson syndrome is due to mtDNA deletions, which usually occur spontaneously, without germline transmission. Only in about 4% of the cases, single mtDNA deletions are inherited from the mother’s side (2). Duplications are also a rare event, but may occur more frequently than point mutations (3, 4). With regard to the phenotype of Pearson syndrome, it has to be stressed that it is not confined to the bone marrow and the pancreas as originally reported, but is in fact a multisystem disease (Table 1) (5). Affected organs other than the bone marrow and the pancreas include the kidneys (Fanconi syndrome (glucosuria, hyperphosphatemia, proteinuria, aminoaciduria), renal insufficiency, global sclerosis of glomerula, 3-methyl glutaconic aciduria (6), tubulopathy and tubular atrophy) (5), the liver (steatosis (6), liver dysfunction (6), hepatomegaly (6), or vacuolated hepatocytes) (6, 7, 8), the central nervous system (seizures, ataxia, retarded speech development, muscle hypotonia, hypointensities of the brain stem, or subcortical white matter lesions with white or grey matter lesions (9), or as movement disorders, particularly tremor) (9), the eyes (retinal or corneal compromise (9), corneal endothelial dysfunction) (8), the endocrine organs (growth retardation with short stature, diabetes, hypoparathyroidism (9), or adrenal insufficiency) (10), the heart (myocardial thickening, repolarisation abnormalities, QT-prolongation, bicuspid right ventricle (9), or as complex–IV deficiency) (6), the blood (anemia, leucopenia, thrombocytopenia, acute myeloid leukemia) (9), the skin (focal hyperpigmentation, café aux lait spots (9), or as cutaneous zygomatosis (11)), the gastro-intenstinal tract (duodenal ulcer, diarrhea (12, 13), reflux, or malabsorption (Table 1), the skeletal muscle (ptosis, muscle weakness, or myopathy (6)), or other abnormalities (e.g. splenomegaly (9)).
Table 1.

Phenotypic manifestations of patients with Pearson syndrome

Organ/tissueAbnormalityFrequencyReference
Central nervous system
Epilepsy+[12]
Ataxia+[14]
Movement disorder (tremor)+[14]
Hypotonia++[15]
Failure to thrive++[15]
Diffuse white matter lesions+[15]
Subcortical white matte lesions+[9]
Delayed motor milestones++[14,15]
Attention deficit+[12]
Hypomyelination (PLIC)+[15]
Leigh-like features+[9,16]
Hypointensities of brain stem, cerebellum, pons+[9,14]
Cortical blindness+[12]
Cerebral atrophy+[12]
Basal ganglia calcification+[14]
Lactic acidosis+++[15]
Peripheral nervous system
Myopathy+[6]
Ptosis+[13]
Absent deep tendon reflexes+[15]
Eyes
Corneal opacities++[8,9,17]
Retinal compromise+[9]
Endocrine organs
Diabetes+++[5]
Growth retardation (short stature)+++[9,13,15]
Adrenal insufficiency++[10,17]
Hypoparathyroidism+[9]
Heart
Complete heart block+[18]
Right (left) myocardial thickening+[9,13,15]
Repolarisation abnormalities+[9]
QT-prolongation+[9]
Bicuspid right ventricle+[9]
Gastrointestinal
Exocrine pancreas insufficiency+++[15]
Steatosis+++[16]
Hepatomegaly++[15]
Malabsorption++[15]
Liver dysfunction+++[6,8]
Vacuolated hepatocytes+[6]
Reflux++[15]
Duodenal ulcer+[12]
Diarrhoea++[12]
Kidneys
Renal cysts+[19]
Tubulopathy+++[5]
Fanconi syndrome++[6]
Renal insufficiency+[6]
Global sclerosis of glomerula+[6]
Blood
Anemia+++[9,13]
Leucopenia+++[9]
Thrombocytopenia+++[9]
Skin
Hyperpigmentation+[9]
Café au lait spots+[9]
Other
Hypospadia+[20]
Cleft lip/palate+[20]
Serum lactate ↑+++[15]
Urine organic acids ↑++[15]
3-methly-glutaconic aciduria++[6]
Splenomegaly+[9]
Acute myeloid leukemia+[9]
Since most organs can be clinically or subclinically affected in Pearson syndrome (Table 1), it is essential to investigate patients with Pearson syndrome prospectively for central nervous system involvement, endocrine abnormalities, kidney disease, cardiac compromise, renal disease, skin abnormalities, gastrointestinal compromise, myopathy, and for ophthalmologic disease. Were prospective investigations for subclinical disease in any organ/tissue in the described patient carried out, and were any phenotypic manifestations in addition to bone marrow dysfunction and pancreas insufficiency detected as listed in Table 1? The patient is reported to have had developed hepatomegaly (1), which has been only rarely previously reported (Table 1). Was hepatomegaly due to primary hepatic compromise or secondary due to heart failure? Heart failure cannot be excluded since the presented patient had been admitted for dyspnea and cyanosis (1). Which were the ECG and echocardiographic findings? Overall, this interesting report could benefit from provision of prospective investigations for multiorgan involvement, and a comprehensive discussion of previously reported data, including the broad phenotypic heterogeneity between patients.
  20 in total

1.  Early onset of complete heart block in Pearson syndrome.

Authors:  S Rahman; J V Leonard
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

2.  Pearson syndrome and the role of deletion dimers and duplications in the mtDNA.

Authors:  L J A M Jacobs; R J E Jongbloed; F A Wijburg; J B C de Klerk; J P M Geraedts; J G Nijland; H R Scholte; I F M de Coo; H J M Smeets
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

3.  The neurological evolution of Pearson syndrome: case report and literature review.

Authors:  Hsiu-Fen Lee; Huei-Jane Lee; Ching-Shiang Chi; Chi-Ren Tsai; Te-Kau Chang; Chau-Jong Wang
Journal:  Eur J Paediatr Neurol       Date:  2007-04-16       Impact factor: 3.140

4.  Cutaneous zygomycosis in an infant with Pearson syndrome.

Authors:  Kalomoira Kefala-Agoropoulou; Evangelia Farmaki; John Tsiouris; Emmanuel Roilides; Aristea Velegraki
Journal:  Pediatr Blood Cancer       Date:  2008-04       Impact factor: 3.167

5.  Clinical implications of duplicated mtDNA in Pearson syndrome.

Authors:  K Muraki; N Sakura; H Ueda; H Kihara; Y Goto
Journal:  Am J Med Genet       Date:  2001-01-22

Review 6.  Genetic Counselling for Maternally Inherited Mitochondrial Disorders.

Authors:  Joanna Poulton; Josef Finsterer; Patrick Yu-Wai-Man
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

7.  Pearson syndrome: altered tricarboxylic acid and urea-cycle metabolites, adrenal insufficiency and corneal opacities.

Authors:  A Ribes; E Riudor; R Valcárel; A Salvá; F Castelló; S Murillo; C Dominguez; A Rötig; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

8.  Pearson Syndrome: A Retrospective Cohort Study from the Marrow Failure Study Group of A.I.E.O.P. (Associazione Italiana Emato-Oncologia Pediatrica).

Authors:  Piero Farruggia; Andrea Di Cataldo; Rita M Pinto; Elena Palmisani; Alessandra Macaluso; Laura Lo Valvo; Maria E Cantarini; Assunta Tornesello; Paola Corti; Francesca Fioredda; Stefania Varotto; Baldo Martire; Isabella Moroni; Giuseppe Puccio; Giovanna Russo; Carlo Dufour; Marta Pillon
Journal:  JIMD Rep       Date:  2015-08-04

9.  Brain lesions of the Leigh-type distribution associated with a mitochondriopathy of Pearson's syndrome: light and electron microscopic study.

Authors:  I Yamadori; A Kurose; S Kobayashi; M Ohmori; T Imai
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

10.  Early neurological impairment and severe anemia in a newborn with Pearson syndrome.

Authors:  Anne-Sophie Morel; Nadia Joris; Reto Meuli; Sébastien Jacquemont; Diana Ballhausen; Luisa Bonafé; Sarah Fattet; Jean-François Tolsa
Journal:  Eur J Pediatr       Date:  2008-06-14       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.